Supercritical CO₂ · Continuous encapsulation

Encapsulation that scales

From the lab bench to the production line

EncapX® encapsulates sensitive active ingredients in liposomes and lipid nanoparticles, continuously, with a patented supercritical CO₂ process. One process from R&D to industrial manufacturing, with no toxic solvents

Discuss your project Discover EncapX®

>97%
encapsulation efficiency
±3%
size variation
60-150 nm
particle size
35 °C
process temperature

COSMETIC 360 Innovation Award 2026

Industry & Process

REGENERATIONS Jury's Coup de cœur

Member of ETPN · France BioLead · AFSSI · BIC · Eurobiomed

Presented at World Vaccine Congress Europe · BIOPC · LNP Development Summit Europe · Festival of Biologics · EMSF

Biotech One in one minute

Fragile molecules need protection. We have made it industrial

Vitamins, mRNA, peptides, plant extracts: many of the most valuable active ingredients degrade before they can act. Encapsulating them in nanoparticles protects them. The hard part was doing it reliably, at scale, with no clogging by design and no toxic solvents.

01 · The problem
Actives degrade
Heat, light, oxygen and the body itself break down sensitive molecules. Today's encapsulation methods clog, use organic solvents and must be redeveloped at every scale.
02 · Our answer
EncapX®, a continuous system
Our patented system encapsulates the active ingredient in liposomes or lipid nanoparticles, continuously, using supercritical CO₂ instead of toxic solvents.
03 · The result
From lab to production
Stable, uniform nanoparticles, and the same process from the first test batch to industrial manufacturing. Industrial groups and research labs already work with us.

Biotech One in two minutes · Fabien Balme, CEO · in French

The product

EncapX®

Continuous supercritical CO₂ encapsulation system

An automated platform built around patented millifluidic channels, about 1,000 times wider than microfluidic ones. No clogging, narrow size distribution and a GMP-compatible design.

Carriers: Liposomes · LNPs
Particle size: ~60-150 nm
Operating mode: Continuous, fully automated
Compatible actives: mRNA · siRNA · antisense RNA · proteins · peptides · vitamins
Scale: R&D → industrial

See performance & specifications

Continuousno batch-to-batch drift
Clog-freemillifluidic channels
GMP-compatible designpressure, temperature, flow control

How it works

Supercritical CO₂ does the hard work

Above 31 °C and 74 bar, CO₂ has the density of a liquid and the diffusivity of a gas. It is non-toxic and leaves no residue. EncapX® turns it into a precise formulation tool.

01 · Feed
Feed
Lipids, your active ingredient and an aqueous phase enter the system with supercritical CO₂.
02 · Form
Form
In pressure-controlled millifluidic channels, vesicles self-assemble around the active ingredient, continuously, at 35 °C.
03 · Collect
Collect
CO₂ returns to a gas and leaves no residue. Uniform nanoliposomes or LNPs come out ready for formulation.

Explore the technology

Why it matters

Removing the trade-off between quality and scale

	EncapX®	Microfluidics	Thin-film hydration (batch)
Continuous production	Yes	Limited	No
Clogging	None, by design	Clogging risk	n/a
Toxic organic solvents	None	Organic solvents usually required	Organic solvents required
Same process from lab to industry	Yes	Parallelisation needed	Redevelopment needed
Size control	±3%	Good at small scale	Broad, extra steps (extrusion or sonication)
Consumables to replace	None	Chips or cartridges	n/a

Applications

One platform for every industry with a fragile active to protect

Pharma & biotech

Reproducible LNPs and liposomes for RNA, proteins, peptides and small molecules, with no redevelopment at scale.

mRNA
siRNA
Peptides
Antibodies

Cosmetics

Stabilise retinol, vitamin C and antioxidants with a greener process.

Retinol
Vitamin C

Food & nutraceuticals

Protect vitamins, omega-3 and plant extracts from oxidation, mask tastes and control release.

Vitamins
DHA
Pigments
Probiotics

Research & academia

A new, publishable formulation method on a lab equipment budget.

Equipment
Publications

Add a continuous LNP and liposome capability to your offer, starting with a feasibility study

Start where you are

An offer for every stage of your development

01 · Screening
A feasibility study on your active ingredient.
Feasibility study
Request a feasibility study
02 · Development
Formulation and process optimisation.
Process development
03 · Scale-up
Pilot and demonstration batches.
Pilot batches
04 · Manufacturing
An EncapX® system on your site.
System sale, installation and support

Technology platforms

Three supercritical CO₂ platforms, built for industry

Available now

EncapX®

Continuous encapsulation of active ingredients in nanoliposomes and lipid nanoparticles.

R&D partnerships

Extract-X®

Clean extraction and fractionation of sensitive compounds, including continuous extraction from algae without drying.

R&D partnerships

Sterili-X®

Low-temperature CO₂ sterilisation of heat-sensitive materials and medical devices.

Science you can check

Rooted in supercritical fluids research at Aix-Marseille University

Our process builds on the work of Prof. Elisabeth Badens, Editor-in-Chief of The Journal of Supercritical Fluids. The EncapX® continuous millifluidic process was patented and validated in 2025.

All publications

2023
Supercritical millifluidic process for siRNA encapsulation in nanoliposomes
Journal of Drug Delivery Science and Technology · 87, 104804
2024
Supercritical millifluidic process for lipid-based formulations of anti-cancer drugs
20th European Meeting on Supercritical Fluids · Maribor
2026
Biotech One révolutionne l'encapsulation des substances actives
Press · Le Journal des Entreprises, June 2026

Company at a glance